Menu
Menu
Flu A/B with SARS-CoV-2 and RSV
Alternate Name: FluVidRsvPANTHER
SAL Code:
2424
CPT:
87637
Loinc:
95941-1
Turn Around Time:
1 Day
Setup:
Daily
Department:
Respiratory Pathogens
Performing Laboratory:
Sherman Abrams Laboratory
Methodology:
Polymerase Chain Reaction (RT-PCR)
Specimen Requirements:
Primary Tube:
VTM
Primary Substance:
Nasopharyngeal
Alternate Sample Info:
UTM
Temperature
Period
Stable Ambient:
1 Day
Stable Fridge:
4 Days
Rejection Criteria:
Improper labeling, expired collection devices, leaking containers, obvious PCR inhibitors, samples that fail internal controls for having sufficient DNA material, any collection devices besides VTM or UTM.
Clinical Info:
Respiratory viruses like SARS-CoV-2, influenza, and RSV are common causes of acute respiratory infections. COVID-19, associated with SARS-CoV-2, shares symptoms with influenza and RSV, making diagnosis without proper testing challenging. COVID-19, declared a pandemic by the World Health Organization on March 11, 2022, exhibits various symptoms, including fever, cough, difficulty breathing, and loss of taste and smell.
RSV is a leading cause of respiratory infections in infants and children, with types A and B causing wintertime epidemics. RSV can lead to severe illness, resulting in numerous hospitalizations for both children and adults. Influenza A and B viruses are primary causes of the flu, with type A usually dominant in wintertime. Symptoms appear one to two days after exposure, and airborne droplets from coughing and sneezing are the primary modes of transmission.
RSV and influenza illnesses can be severe in young, elderly, and immunocompromised patients. Swift and accurate testing is crucial for rapid diagnosis and treatment.
Additional Information:
The SARS-CoV-2/Flu A/B/RSV assay is a multiplex real-time Polymerase Chain Reaction (RT-PCR) test. It is designed to qualitatively identify and differentiate RNA from SARS-CoV-2, influenza A virus (Flu A), influenza B virus (Flu B), and respiratory syncytial virus (RSV). The RNA is extracted and purified from nasopharyngeal (NP) swab specimens collected from individuals showing signs and symptoms of respiratory tract infections. Negative results should not be solely relied upon, as they do not rule out the possibility of newly acquired SARS-CoV-2, influenza A virus, influenza B virus, or RSV infections. Please consider the patients full clinical presentation and potential exposure when considering these results.
Sample Collection:
Collect nasopharyngeal swab specimens using a polyester, rayon, or nylon-tipped swab following standard technique, and immediately place into 3mL of VTM or UTM. DO NOT USE ANY OTHER MEDIA. Samples received in any media other than VTM or UTM will be rejected.
Test Limitations:
1. Reliable outcomes are dependent on proper specimen collection, transportation, storage, and processing.
2. Negative results do not rule out SARS-CoV-2, influenza A virus, influenza B virus, or RSV infections and should not be the sole basis for treatment or management decisions.
3. This test does not distinguish between influenza A subtypes (e.g., H1N1, H3N2) or RSV subgroups (e.g., A or B).
4. A positive result indicates the detection of nucleic acid from the relevant virus. Nucleic acid may persist even after the virus is no longer viable.
Please interpret all results in light of patient's clinical presentation, history, and potential recent exposure.
Test Information:
Components:
| Component Name | CPT | Loinc |
| Influenza A | 85477-8 | Influenza B | 85478-6 | Respiratory Syncytial Virus (RSV) | 85479-4 | SARS-CoV-2 | 94500-6 |
